Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study.
A retrospective study was performed on 69 breast cancer patients (stage II, N = 18; advanced disease, N = 51) in order to assess the prognostic value of circulating prolactin (PRL), CEA, CA 15-3, insulin-like growth factor-1 (IGF-1), and epidermal growth factor (EGF) by RIA/IRMA. These markers were compared with short-term prognosis (two years). Significant difference was observed only for PRL ( < 20.0 ng/ml vs. > 20.0 ng/ml), which provide an independent predictor of short-term prognosis in advanced breast cancer.
Bhatavdekar
J M
JM
Division of Research, Gujarat Cancer Society, Asarwa, Ahmedabad, India.
Patel
D D
DD
Karelia
N H
NH
Vora
H H
HH
Ghosh
N
N
Shah
N G
NG
Balar
D B
DB
Trivedi
S N
SN
D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology; D002272:Carcinoembryonic Antigen / Q000097:blood; D004815:Epidermal Growth Factor / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D015592:Immunoradiometric Assay; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D018396:Mucin-1 / Q000097:blood; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011388:Prolactin / Q000097:blood; D011863:Radioimmunoassay; D012016:Reference Values; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D011388:Prolactin